Exchange & Returns Information
Review Details
(32)
| Drug Type | Original |
|---|---|
| Active Ingredient | SEMAGLUTIDE |
| Strength | 0.5MG |
| Manufacturer | NOVO NORDISK |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 129.00 | $ 129.00 |
$ 109.65
Apply ZARVY26 (-15%)
You save $ 19.35
|
||
| 2 BOXES - 2 PENS | $ 99.50 |
23% $ 258.00
$ 199.00
|
$ 169.15
Apply ZARVY26 (-15%)
You save $ 29.85
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 86.33 |
33% $ 387.00
$ 259.00
|
$ 220.15
Apply ZARVY26 (-15%)
You save $ 38.85
|
Reference information will be available soon.
Ozempic 0.5mg Prefilled Pen is a once-weekly injectable formulation of semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist indicated for adults with type 2 diabetes mellitus. This dose represents the first therapeutic stage following initiation (0.25mg) and is widely used to achieve clinically meaningful glycemic control. By stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, and delaying gastric emptying, semaglutide improves postprandial glycemic response and overall HbA1c levels. Ozempic has also demonstrated cardiovascular risk reduction in patients with established heart disease. Although patients may experience weight loss while on Ozempic, it is not FDA-approved for obesity treatment, and any weight control benefit is to be considered off-label.
- DIABETES (GLP-1 Receptor Agonists) > Ozempic 0.5mg is approved for the management of type 2 diabetes in adults. It is used either as monotherapy (in metformin-intolerant patients) or as an adjunct to oral antidiabetic medications. This dose helps lower fasting and postprandial glucose levels while offering once-weekly convenience and a low risk of hypoglycemia. Clinical trials also support its use for reducing major cardiovascular events in high-risk diabetic populations. - DIET (Metabolic Weight Control) > While semaglutide's appetite-suppressing properties have shown significant weight loss outcomes, Ozempic is not approved for weight management. Off-label usage exists, but Wegovy remains the only semaglutide-based product authorized for obesity treatment. Any fat loss experienced during Ozempic therapy is incidental.
Semaglutide acts by binding to GLP-1 receptors in pancreatic beta cells, enhancing glucose-dependent insulin secretion, while simultaneously suppressing the secretion of glucagon from alpha cells. This dual mechanism helps reduce both fasting and meal-time glucose levels without causing hypoglycemia in the absence of sulfonylureas or insulin. It also slows gastric emptying, improving satiety and post-meal glucose stability. Beyond glycemic control, semaglutide influences appetite centers in the brain, which explains its observed but off-label impact on body weight. The 0.5mg dose represents the functional baseline for most patients requiring long-term diabetes management.
→ Subcutaneous Injection for Type 2 Diabetes (Ozempic-specific): - Week 1–4: 0.25 mg SC once weekly (initiation phase) - Week 5–8 and beyond: 0.5 mg SC once weekly *(This product applies here)* - Optional: Increase to 1.0 mg SC weekly if further glucose control is needed - Max Dose: 1.0 mg per week → Switching Guidance: - From oral semaglutide (14 mg): begin 0.5 mg SC Ozempic one week after last oral dose - From 0.5 mg SC Ozempic → oral 7 or 14 mg semaglutide: begin within 7 days of final injection - No oral equivalent for 1.0 mg SC dose → Indication Criteria: - Adults with type 2 diabetes mellitus, especially those inadequately managed with oral agents - Patients with cardiovascular comorbidities or high ASCVD risk → Off-Label Use for Weight Loss: - Although weight reduction may occur, this is not the intended therapeutic outcome for Ozempic - Clinicians seeking weight loss as a primary goal should consider Wegovy, not Ozempic
Refrigerate unopened pens at 2–8°C. Do not freeze. Once opened, the pen may be stored at room temperature (up to 30°C) for a maximum of 56 days. Protect from heat and light. Keep out of reach of children.
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite—most frequently observed during initial dose escalation. These are generally mild and transient. Less common reactions include dyspepsia, injection site irritation, fatigue, and dizziness. Serious adverse events may involve pancreatitis, gallbladder disease, or renal complications due to dehydration. Hypoglycemia is uncommon unless combined with insulin or insulin secretagogues. Patients should be monitored for signs of persistent gastrointestinal distress or signs of allergic or hypersensitivity reactions.
I had some questions about potential side effects when stepping up to the 0.5mg dose. I reached out to customer service, and they were incredibly professional. They couldn't give medical advice, of course, but they directed me to helpful resources on their site and assured me about the product's authenticity. This responsive and caring support, combined with flawless delivery, makes them feel like a true partner in my health journey.
The 0.5mg dose has been great for curbing my afternoon snack cravings. A very welcome change.
The refrigerated packaging is always top-notch. I have full confidence in the medication I receive from this site.
I'm not a doctor, but I feel like my energy levels are more consistent since starting Ozempic. A great feeling.
I'm always impressed with how efficiently they handle Canadian orders. No issues at all.
No combo deals available at the moment.
